Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.42 |
| ▸ | MMP2 | P08253 | 5/20 | 0.42 |
| ▸ | NPY4R | P50391 | 6/20 | 0.41 |
| ▸ | NPY1R | P25929 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219789 | 1.00 | SIRT5 (0.42) | SIRT5MMP2NPY4RNPY1RPOLB | |
| SCHEMBL12514977 | 0.98 | MMP2 (0.43) | SIRT5MMP2NPY4RNPY1RPOLB | |
| SCHEMBL12518601 | 0.98 | MMP2 (0.43) | SIRT5MMP2NPY4RNPY1RPOLB | |
| SCHEMBL19219798 | 0.93 | MMP2 (0.45) | SIRT5MMP2NPY4RNPY1RNPY2R | |
| SCHEMBL19219801 | 0.93 | MMP2 (0.45) | SIRT5MMP2NPY4RNPY1RNPY2R | |
| SCHEMBL19944786 | 0.93 | MMP2 (0.45) | SIRT5MMP2NPY4RNPY1RNPY2R | |
| SCHEMBL21371594 | 0.93 | SIRT5 (0.47) | SIRT5MMP2POLB | |
| SCHEMBL19486026 | 0.93 | SIRT5 (0.47) | SIRT5MMP2POLB | |
| SCHEMBL12514981 | 0.91 | MMP2 (0.46) | MMP2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL12514973 | 0.91 | MMP2 (0.46) | MMP2NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | SIRT5 964/4885MMP2 595/4885NPY4R 4874/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | SIRT5 964/4885MMP2 595/4885NPY4R 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.